SCHEMBL6202118

SCHEMBL6202118

Cc1cccc2[nH]c(=O)c(C(=O)N(C)c3ccccc3)c(O)c12

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.43
PGR P06401 1/20 0.43
KMT2A Q03164 1/20 0.43
MAP3K5 Q99683 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
PTGS2 P35354 1/20 0.40
DAO P14920 2/20 0.40
DDO Q99489 2/20 0.40
KDM5A P29375 1/20 0.39
KDM4E B2RXH2 3/20 0.38
TDP1 Q9NUW8 1/20 0.38
PARP1 P09874 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15200742 0.90 KMT2A (0.43) MEN1PGRKMT2AMAP3K5NPC1
SCHEMBL39522 0.88 GRIN2D (0.49) MEN1PGRKMT2AMAP3K5PTGS2
SCHEMBL9267768 0.86 DAO (0.39) MAP3K5NPC1RAB9ADAODDO
SCHEMBL7818937 0.85 PTGS2 (0.44) MEN1PGRKMT2AMAP3K5NPC1
SCHEMBL2485564 0.84 MEN1 (0.45) MEN1KMT2AMAP3K5NPC1RAB9A
SCHEMBL852747 0.83 KMT2A (0.55) MEN1PGRKMT2ANPC1RAB9A
SCHEMBL7862448 0.83 KMT2A (0.38) MEN1PGRKMT2ANPC1PTGS2
SCHEMBL2483507 0.81 KDM4E (0.50) KMT2AMAP3K5NPC1RAB9ADAO
SCHEMBL7563981 0.79 GPBAR1 (0.40) MEN1PGRKMT2APTGS2KDM4E
SCHEMBL7829055 0.78 PTGS2 (0.40) MEN1PGRKMT2APTGS2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0634931-A1 THE USE OF QUINOLINE-3-CARBOXAMIDE COMPOUNDS FOR TREATMENT OF DIABETES Pharmacia & Upjohn Aktiebolag (SE) 1995-01-25 EP claimed
WO-1993019756-A9 THE USE OF QUINOLINE-3-CARBOXAMIDE COMPOUNDS FOR TREATMENT OF DIABETES 1994-10-27 WO claimed
WO-1993019756-A1 THE USE OF QUINOLINE-3-CARBOXAMIDE COMPOUNDS FOR TREATMENT OF DIABETES KABI PHARMACIA AB (SE) 1993-10-14 WO claimed
EP-1511732-A1 PROCESS FOR THE MANUFACTURE OF QUINOLINE DERIVATIVES Active Biotech AB (SE) 2005-03-09 EP disclosed
WO-2003106424-A1 PROCESS FOR THE MANUFACTURE OF QUINOLINE DERIVATIVES ACTIVE BIOTECH AB (SE) 2003-12-24 WO disclosed
EP-1224172-A1 DRUGS FOR THE TREATMENT OF MALIGNANT TUMOURS Active Biotech AB (SE) 2002-07-24 EP disclosed
WO-2001030758-A1 DRUGS FOR THE TREATMENT OF MALIGNANT TUMOURS ACTIVE BIOTECH AB (SE) 2001-05-03 WO disclosed
EP-0758327-A1 PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 1997-02-19 EP disclosed
EP-0682663-A1 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 1995-11-22 EP disclosed
WO-1993019756-A9 THE USE OF QUINOLINE-3-CARBOXAMIDE COMPOUNDS FOR TREATMENT OF DIABETES 1994-10-27 WO disclosed
EP-0516725-A1 NEW USE. KABI PHARMACIA AB (SE) 1992-12-09 EP disclosed
WO-1991012804-A1 NEW USE KABI PHARMACIA AB (SE) 1991-09-05 WO disclosed